However, the feasibility, outcome prediction, and guidance of pre-emptive therapy based on IDH1/2-MRD in AML patients was rarely investigated and thus cannot be recommended, mainly due to the concern of IDH1/2 mutants as pre-leukemic clones as well as the possibility of loss or gain of IDH1/2 mutants at relapse [26]. The gene discussed is IDH1; the disease is acute myeloid leukemia.